Trial Profile
Molecular Mechanisms Underlying Tumor Progression Despite Enzalutamide Treatment
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 02 Aug 2023
Price :
$35
*
At a glance
- Drugs Enzalutamide (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Pharmacodynamics; Pharmacogenomic
- 27 Jul 2023 Planned End Date changed from 1 Jun 2023 to 1 Jun 2024.
- 17 Jun 2022 Planned End Date changed from 1 Jun 2022 to 1 Jun 2023.
- 20 May 2021 Planned End Date changed from 1 Jun 2021 to 1 Jun 2022.